Literature DB >> 28138651

Treatment of refractory gastrointestinal stromal tumor using pazopanib.

Irvin C Lien1, Seth M Pollack2.   

Abstract

Entities:  

Year:  2016        PMID： 28138651      PMCID： PMC5244707          DOI： 10.21037/tgh.2016.11.01

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  12 in total

1.  A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.

Authors:  K N Ganjoo; V M Villalobos; A Kamaya; G A Fisher; J E Butrynski; J A Morgan; A J Wagner; D D'Adamo; A McMillan; G D Demetri; S George
Journal:  Ann Oncol       Date:  2014-01       Impact factor: 32.976

2.  Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden.

Authors:  Bengt Nilsson; Per Bümming; Jeanne M Meis-Kindblom; Anders Odén; Aydin Dortok; Bengt Gustavsson; Katarzyna Sablinska; Lars-Gunnar Kindblom
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

3.  Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.

Authors:  Olivier Mir; Claire Cropet; Maud Toulmonde; Axel Le Cesne; Mathieu Molimard; Emmanuelle Bompas; Philippe Cassier; Isabelle Ray-Coquard; Maria Rios; Antoine Adenis; Antoine Italiano; Olivier Bouché; Emmanuelle Chauzit; Florence Duffaud; François Bertucci; Nicolas Isambert; Julien Gautier; Jean-Yves Blay; David Pérol
Journal:  Lancet Oncol       Date:  2016-04-05       Impact factor: 41.316

4.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  George D Demetri; Peter Reichardt; Yoon-Koo Kang; Jean-Yves Blay; Piotr Rutkowski; Hans Gelderblom; Peter Hohenberger; Michael Leahy; Margaret von Mehren; Heikki Joensuu; Giuseppe Badalamenti; Martin Blackstein; Axel Le Cesne; Patrick Schöffski; Robert G Maki; Sebastian Bauer; Binh Bui Nguyen; Jianming Xu; Toshirou Nishida; John Chung; Christian Kappeler; Iris Kuss; Dirk Laurent; Paolo G Casali
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

5.  KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.

Authors:  Ketan S Gajiwala; Joe C Wu; James Christensen; Gayatri D Deshmukh; Wade Diehl; Jonathan P DiNitto; Jessie M English; Michael J Greig; You-Ai He; Suzanne L Jacques; Elizabeth A Lunney; Michele McTigue; David Molina; Terri Quenzer; Peter A Wells; Xiu Yu; Yan Zhang; Aihua Zou; Mark R Emmett; Alan G Marshall; Hui-Min Zhang; George D Demetri
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-21       Impact factor: 11.205

6.  Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.

Authors:  M Montemurro; H Gelderblom; U Bitz; J Schütte; J Y Blay; H Joensuu; J Trent; S Bauer; P Rutkowski; F Duffaud; D Pink
Journal:  Eur J Cancer       Date:  2012-11-06       Impact factor: 9.162

Review 7.  The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.

Authors:  Toshirou Nishida; Jean-Yves Blay; Seiichi Hirota; Yuko Kitagawa; Yoon-Koo Kang
Journal:  Gastric Cancer       Date:  2015-08-15       Impact factor: 7.370

Review 8.  Gastrointestinal stromal tumor.

Authors:  Michael Stamatakos; Emmanouel Douzinas; Charikleia Stefanaki; Panagiotis Safioleas; Electra Polyzou; Georgia Levidou; Michael Safioleas
Journal:  World J Surg Oncol       Date:  2009-08-01       Impact factor: 2.754

9.  Prognosis and predictive value of KIT exon 11 deletion in GISTs.

Authors:  J-B Bachet; I Hostein; A Le Cesne; S Brahimi; A Beauchet; S Tabone-Eglinger; F Subra; B Bui; F Duffaud; P Terrier; J-M Coindre; J-Y Blay; J-F Emile
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

10.  Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST).

Authors:  B Nilsson; K Sjölund; L-G Kindblom; J M Meis-Kindblom; P Bümming; O Nilsson; J Andersson; H Ahlman
Journal:  Br J Cancer       Date:  2007-05-29       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.